JPH01213227A - Ointment and solution - Google Patents
Ointment and solutionInfo
- Publication number
- JPH01213227A JPH01213227A JP3862388A JP3862388A JPH01213227A JP H01213227 A JPH01213227 A JP H01213227A JP 3862388 A JP3862388 A JP 3862388A JP 3862388 A JP3862388 A JP 3862388A JP H01213227 A JPH01213227 A JP H01213227A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- salt
- ointment
- antihistaminic agent
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 16
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 33
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 32
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 32
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 239000003883 ointment base Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims description 17
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 14
- 230000001387 anti-histamine Effects 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 12
- 206010048218 Xeroderma Diseases 0.000 abstract description 12
- 206010021198 ichthyosis Diseases 0.000 abstract description 12
- 229940125715 antihistaminic agent Drugs 0.000 abstract description 10
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 abstract description 6
- 229940046978 chlorpheniramine maleate Drugs 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 206010020649 Hyperkeratosis Diseases 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000001126 Keratosis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 230000007803 itching Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- -1 vaseline Chemical compound 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RZENSCAUEVAXIQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-2-(pyrrolidin-1-ylmethyl)benzimidazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 RZENSCAUEVAXIQ-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- CPHGOBGXZQKCKI-UHFFFAOYSA-N 4,5-diphenyl-1h-imidazole Chemical compound N1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CPHGOBGXZQKCKI-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Chemical group O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical group O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000037852 mild atopic dermatitis Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明はヒアルロン酸又その塩と抗ヒスタミン剤とを含
む軟膏剤及び液剤に関し、更に詳しくは老人性乾皮症、
皮膚角化症、軽症のアトピー性皮膚炎等の治療に有用で
ある軟膏剤及び液剤に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to ointments and liquids containing hyaluronic acid or its salts and an antihistamine, and more specifically to senile xeroderma,
The present invention relates to ointments and liquids useful for the treatment of skin keratosis, mild atopic dermatitis, etc.
（従来の技術及びその問題点）
従来、住宅環境の整備や都市環境の緑地帯の減少等種々
の原因により、冬期の低湿度化が進行すると共に、人体
の皮膚の乾燥状態が進み、特に老人においては皮膚の老
化と共に、低湿度化によって老人性乾皮症や皮膚角化症
等の症例が増加している。(Prior art and its problems) Conventionally, due to various causes such as improving housing environments and decreasing green areas in urban environments, the humidity in winter has progressed, and the human skin has become dry, especially in the elderly. In addition to skin aging, cases of senile xeroderma and skin keratosis are increasing due to low humidity.
これらの乾皮症等の対策としては皮膚表面に水分を十分
に補給すると共に、皮膚の水分を保持することが重要で
あり、これらの目的でプロピレングリコール、１．３−
ブチレングリコール、ピロリドンカルボン酸、ヒアルロ
ン酸等を含む保湿剤が提供されており、これらの中では
ヒアルロン酸を含有する外用剤が最も良好なものとして
広く使用されるようになって来た。As a countermeasure against xeroderma, etc., it is important to supply sufficient moisture to the skin surface and retain moisture in the skin. For these purposes, propylene glycol, 1.3-
Moisturizing agents containing butylene glycol, pyrrolidone carboxylic acid, hyaluronic acid, etc. have been provided, and among these, external preparations containing hyaluronic acid have become the most suitable and have been widely used.
以上の如き従来の保湿剤は、美容上皮膚の保護や美化に
は良い成績を示すものの、前述の如き老人性乾皮症等の
治療には十分な効果を示さず、特に皮膚の乾燥によって
生じるかゆみ等の問題には殆ど効果を示さないという問
題点があった。Although conventional moisturizers such as those mentioned above show good results in cosmetically protecting and beautifying the skin, they are not sufficiently effective in treating conditions such as senile xeroderma, which is caused by dryness of the skin. The problem was that it had little effect on problems such as itching.
一方、皮膚のかゆみ等の治療には抗ヒスタミン剤が一般
的に使用されているが、これらの抗ヒスタミン剤を通用
しても皮膚のかゆみは一時的には抑えられるものの、患
部の根本的治療効果は期待できず、永続的な効果に欠け
るという問題がある。On the other hand, antihistamines are commonly used to treat skin itching, etc., but although these antihistamines can temporarily suppress the skin itching, they cannot be expected to have a fundamental therapeutic effect on the affected area. However, there is a problem in that it lacks lasting effects.
従って本発明の目的は、皮膚の保湿剤として有用であり
、特に老人の乾皮症等の治療に有効な外用薬を提供する
ことである。Therefore, an object of the present invention is to provide a topical drug that is useful as a skin moisturizer and is particularly effective in treating xeroderma and the like in the elderly.
（問題点を解決するための手段） 以下目的は以下の本発明によって達成される。(Means for solving problems) The following objects are achieved by the present invention.
すなわち、本発明は、軟膏基材中にヒアルロン酸又その
塩と抗ヒスタミン剤とを配合したことを特徴とする軟膏
剤及び液剤基材中にヒアルロン酸又その塩と抗ヒスタミ
ン剤とを配合したことを特徴とする液剤である。That is, the present invention provides an ointment characterized by blending hyaluronic acid or a salt thereof and an antihistamine in an ointment base material, and an ointment characterized by blending hyaluronic acid or a salt thereof and an antihistamine in a liquid base. It is a liquid agent.
（作 用）
軟膏剤や液剤の有効成分としてヒアルロン酸又その塩と
抗ヒスタミン剤とを併用することによって、老人の乾皮
症等に対し、十分な保湿性を与えると共に乾皮症特有の
かゆみを無くし患部自体の治療効果が得られる。(Function) By using hyaluronic acid or its salt as an active ingredient in ointments and liquids in combination with antihistamines, it provides sufficient moisture retention for xeroderma in the elderly and eliminates the itching characteristic of xeroderma. A therapeutic effect can be obtained on the affected area itself.
（好ましい実施態様）
次に好ましい実施態様を挙げて本発明を更に具体的に説
明する。(Preferred Embodiments) Next, the present invention will be described in more detail by citing preferred embodiments.
本発明において使用するヒアルロン酸又その塩とは、Ｎ
−アセチルグルコサミンとＤ−グルクロン酸を反復構成
単位とする複雑な多糖類の１種であって、高い吸水性及
び保水性を有し、従来から化粧品の１成分として使用さ
れており、本発明ではこれらの公知のヒアルロン酸又そ
の塩がそのまま使用できる。The hyaluronic acid or its salt used in the present invention is N
- A type of complex polysaccharide with repeating structural units of acetylglucosamine and D-glucuronic acid, which has high water absorption and water retention properties, and has been traditionally used as an ingredient in cosmetics. These known hyaluronic acids or their salts can be used as they are.
又、本発明において上記のヒアルロン酸又その塩と併用
する抗ヒスタミン剤は、ジンマシン、アレルギー性鼻炎
、胃腸管アレルギー、全身アナフィラキシ−１皮膚疾患
に伴うかゆみ、薬物反応によるかゆみ等の治療薬として
知られているものであって、例えば、マレイン酸クロル
フェニラミン、ｄ−マレイン酸クロルフェニラミン、ジ
フェンヒドラミン及び塩類、塩酸イソチベンジル、硫酸
クレミゾール、ジフェニールイミダゾール等が挙げられ
る。Further, in the present invention, the antihistamine used in combination with the above-mentioned hyaluronic acid or its salt is known as a therapeutic agent for ginma, allergic rhinitis, gastrointestinal tract allergy, itching associated with systemic anaphylaxis-1 skin disease, itching due to drug reaction, etc. Examples of these include chlorpheniramine maleate, d-chlorpheniramine maleate, diphenhydramine and its salts, isothibenzyl hydrochloride, clemizole sulfate, diphenylimidazole, and the like.
本発明の軟膏剤及び液剤は上記のヒアルロン酸又その塩
と抗ヒスタミン剤とを軟膏基材や液剤基材中に溶解又は
分散させたことを特徴とするが、両者の使用割合も重要
であって、例えば、ヒアルロン酸又その塩１重量部当り
抗ヒスタミン剤を５０乃至２００重量部の割合で使用す
ることが好ましく、ヒアルロン酸又その塩の使用量が少
な過ぎると使用時の保湿性が不足して抗ヒスタミン剤の
作用を十分に発揮させることができない。又、ヒアルロ
ン酸又その塩の使用量が多過ぎても保湿性は十分である
が、抗ヒスタミン剤の効果が十分でなくなる。The ointment and liquid preparation of the present invention are characterized in that the above-mentioned hyaluronic acid or its salt and an antihistamine are dissolved or dispersed in an ointment base material or a liquid base material, but the usage ratio of both is also important. For example, it is preferable to use the antihistamine at a ratio of 50 to 200 parts by weight per 1 part by weight of hyaluronic acid or its salt; if the amount of hyaluronic acid or its salt used is too small, the moisturizing properties during use will be insufficient, resulting in the use of the antihistamine. The effect cannot be fully exerted. Furthermore, even if the amount of hyaluronic acid or its salt used is too large, the moisturizing properties will be sufficient, but the effect of the antihistamine will not be sufficient.
本発明において上記ヒアルロン酸又その塩及び抗ヒスタ
ミン剤を溶解又は分散させる基材は、目的物が軟膏剤で
ある場合には従来公知の軟膏基材がそのまま使用でき、
例えば、カルボキシメチルセルロースナトリウム塩、ポ
リエチレングリコール等の水溶性高分子物、オリーブ油
等の植物油、ワセリン等の鉱物油、セチルアルコール等
の低級アルコール等を主剤とした従来公知のいずれの軟
膏基材も使用できる。特に好ましいものはカルボキシメ
チルセルロースのナトリウム塩である。In the present invention, as the base material for dissolving or dispersing the above-mentioned hyaluronic acid or its salt and antihistamine, when the target product is an ointment, a conventionally known ointment base can be used as is,
For example, any conventionally known ointment base material can be used, which is based on carboxymethyl cellulose sodium salt, water-soluble polymers such as polyethylene glycol, vegetable oils such as olive oil, mineral oils such as vaseline, lower alcohols such as cetyl alcohol, etc. . Particularly preferred is the sodium salt of carboxymethyl cellulose.
又、本発明の組成物が液状である場合には、従来公知の
ローション基材、液剤の基材等がそのまま使用できる。Furthermore, when the composition of the present invention is in liquid form, conventionally known lotion base materials, liquid agent base materials, etc. can be used as they are.
更に本発明では前記のヒアルロン酸又その塩、抗ヒスタ
ミン剤及び基材に加えて必要に応じて一般の薬剤、軟膏
剤、液剤等に添加されている各種の安定材や保存材等の
添加剤も含有し得るのは当然である。Furthermore, in addition to the above-mentioned hyaluronic acid or its salt, antihistamine agent, and base material, the present invention also contains additives such as various stabilizers and preservatives that are added to general medicines, ointments, liquids, etc. as necessary. Of course it can be done.
本発明の組成物においては、組成物全体に対するヒアル
ロン酸又その塩及び抗ヒスタミン剤の濃度も重要であり
、ヒアルロン酸又その塩は全体を１００重量部とした時
に０．０１乃至１重量％を占める割合で使用し、一方、
抗ヒスタミン剤は０．５乃至５重量％を占める割合で使
用するのが好ましい。何れか一方が少な過ぎても多過ぎ
ても両者の相乗効果は満足できなくなる。In the composition of the present invention, the concentration of hyaluronic acid or its salt and the antihistamine agent relative to the entire composition is also important, and the proportion of hyaluronic acid or its salt is 0.01 to 1% by weight when the entire composition is 100 parts by weight. and on the other hand,
The antihistamine is preferably used in an amount of 0.5 to 5% by weight. If either one is too little or too much, the synergistic effect of the two will not be satisfactory.
（効 果）
以上の如き本発明によれば、軟膏剤や液剤の有効成分と
してヒアルロン酸又その塩と抗ヒスタミン剤とを併用す
ることによって、老人の乾皮症等に対し、十分な保湿性
を与えると共に乾皮症特有のかゆみを無くし、患部自体
の治療効果が得られる。勿論本発明の軟膏及び液剤は乾
皮症等の治療に限定されず、それらの予防や皮膚の美容
或いは荒れ性肌荒れ、かみそり負け、かゆみ等の治療や
予防にも有効である。(Effect) According to the present invention as described above, by using hyaluronic acid or its salt and an antihistamine together as active ingredients in ointments and liquids, sufficient moisturizing properties can be provided to treat xeroderma in the elderly. At the same time, it eliminates the itch characteristic of xeroderma and provides a therapeutic effect on the affected area itself. Of course, the ointments and liquid preparations of the present invention are not limited to the treatment of xeroderma, etc., but are also effective for their prevention, skin beautification, and treatment and prevention of rough skin, razor burn, itching, etc.
（実施例） 次に実施例を挙げて本発明を更に詳しく説明する。(Example) Next, the present invention will be explained in more detail with reference to Examples.
実施例１
ヒアルロン酸又はそのナトリウム塩０．１ｇカルボキシ
メチルセルロースナトリウム塩ｇ
マレイン酸クロルフェニラミン １ｇｐ−ヒドロ
キシ安息香酸メチル ０．０２ｇｐ−ヒドロキシ安息香
酸プロピル
０．０１ｇ
エタノール ２ｍｌ精製水
全量が１００ｍ１になる量上記処方にて約
８０ａｌの精製水にヒアルロン酸又はそのナトリウム塩
及びマレイン酸クロルフェニラミンを加え、又、予めエ
タノールに溶解しであるｐ−ヒドロキシ安息香酸メチル
及びｐ−ヒドロキシ安息香酸プロピルを加えて攪拌し溶
解させる。溶解後カルボキシメチルセルロースナトリウ
ム塩と残余の水を加え全体をよく混合して均質化し本発
明の軟膏剤を得た。Example 1 Hyaluronic acid or its sodium salt 0.1 g Carboxymethyl cellulose sodium salt g Chlorpheniramine maleate 1 g Methyl p-hydroxybenzoate 0.02 g Propyl p-hydroxybenzoate 0.01 g Ethanol 2 ml Purified water Amount to make the total volume 100 ml Above Add hyaluronic acid or its sodium salt and chlorpheniramine maleate to approximately 80 al of purified water according to the recipe, and add methyl p-hydroxybenzoate and propyl p-hydroxybenzoate, which have been previously dissolved in ethanol, and stir. and dissolve. After dissolving, carboxymethylcellulose sodium salt and the remaining water were added and the whole was thoroughly mixed and homogenized to obtain an ointment of the present invention.
比較例１
実施例１においてヒアルロン酸又はそのナトリウム塩を
使用しなかったことを除き他は実施例１と同様にして比
較例の軟膏剤を得た。Comparative Example 1 An ointment of a comparative example was obtained in the same manner as in Example 1 except that hyaluronic acid or its sodium salt was not used in Example 1.
実施例２
ヒアルロン酸又はそのナトリウム塩０．１ｇマレイン酸
クロルフェニラミン １ｇグリセリン
１０ｍ１ｐ−ヒドロキシ安息香酸メチル
０．０２ｇＰ−ヒドロキシ安息香酸プロピル
０．０１ｇ
エタノール ２ｍｌ精製水
全量が１００ｍ１になる量上記処方にて約
８０ｍ１の精製水にヒアルロン酸又はそのナトリウム塩
及びマレイン酸クロルフェニラミンを加え、又、予めエ
タノールに溶解しであるｐ−ヒドロキシ安息香酸メチル
及びｐ−ヒドロキシ安息香酸プロピルを加えて攪拌し溶
解させる。溶解後グリセリン塩と残余の水を加え全体を
よく混合して均質化し本発明の液剤を得た。Example 2 Hyaluronic acid or its sodium salt 0.1g Chlorpheniramine maleate 1g Glycerin
10m1p-methyl hydroxybenzoate
0.02 g Propyl P-hydroxybenzoate 0.01 g Ethanol 2 ml Purified water Amount to make the total volume 100 ml Add hyaluronic acid or its sodium salt and chlorpheniramine maleate to about 80 ml of purified water according to the above recipe, and add ethanol in advance. Add methyl p-hydroxybenzoate and propyl p-hydroxybenzoate dissolved in the solution and stir to dissolve. After dissolving, the glycerin salt and the remaining water were added and the whole was thoroughly mixed and homogenized to obtain a liquid preparation of the present invention.
比較例２
実施例２においてヒアルロン酸又けそのナトリウム塩を
使用しなかったことを除き他は実施例２と同様にして比
較例の液剤を得た。Comparative Example 2 A liquid preparation of a comparative example was obtained in the same manner as in Example 2 except that hyaluronic acid or its sodium salt was not used.
使用例
実施例及び比較例の軟膏剤及び液剤を６３才の老人の乾
皮症部分に約５ｇ／ｒｎ’の割合で薄く塗布し、塗布後
５日間の経過を見たところ、次ぎの如き結果を得た。Usage Examples The ointments and liquids of Examples and Comparative Examples were applied thinly to the dry skin area of a 63-year-old elderly man at a rate of about 5 g/rn', and the progress was observed for 5 days after application, and the following results were obtained. I got it.
実施例１：皮膚の乾燥や４痒感が著明に抑制され、従来
抗ヒスタミン剤ではあまり効果が期待できない丘疹や紅
斑に対しても明かな治療効果が認められた。又、患者は
未痒感による精神的なストレスからも著明に開放された
。従ってヒアルロン酸又はその塩を抗ヒスタミン剤に併
用することによって、従来の抗ヒスタミン剤の効果が数
倍（２乃至３倍）にも増強された。Example 1: Skin dryness and itching were significantly suppressed, and a clear therapeutic effect was also observed on papules and erythema, for which conventional antihistamines were not expected to be very effective. In addition, the patient was significantly relieved from the mental stress caused by the feeling of non-pruritus. Therefore, by using hyaluronic acid or a salt thereof in combination with an antihistamine, the effect of conventional antihistamines was enhanced several times (2 to 3 times).
実施例２：実施例１と同様な効果を奏し、更に夏期の使
用においてはさっばりとした使用感があった。Example 2: The same effects as in Example 1 were obtained, and there was also a light feeling when used in the summer.
比較例１：座痒感の抑制効果は有るが、実施例に比較し
てその抑ル１効果は約半分程度であった。Comparative Example 1: Although there was an effect of suppressing the feeling of itching, the suppressing effect 1 was about half that of the example.
又、皮膚の乾燥が止まらず、部位によっては皮膚表面に
亀裂が生じて悪化した。又、丘疹や紅斑に対しては殆ど
効果が無かった。In addition, the dryness of the skin did not stop, and cracks appeared on the skin surface in some areas, which worsened the situation. Furthermore, it had little effect on papules and erythema.
比較例２：比較例１と同様であった。Comparative Example 2: Same as Comparative Example 1.
以上の通り本発明によれば、ヒアルロン酸単独又は抗ヒ
スタミン剤単独のいずれによっても得られない優れた相
乗効果が得られる。As described above, according to the present invention, an excellent synergistic effect that cannot be obtained with either hyaluronic acid alone or antihistamine alone can be obtained.
Claims (2)
ン剤とを配合したことを特徴とする軟膏剤。(1) An ointment characterized by containing hyaluronic acid or its salt and an antihistamine in an ointment base material.
ン剤とを配合したことを特徴とする液剤。(2) A liquid agent characterized in that hyaluronic acid or its salt and an antihistamine agent are blended into the liquid agent base material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3862388A JPH01213227A (en) | 1988-02-23 | 1988-02-23 | Ointment and solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3862388A JPH01213227A (en) | 1988-02-23 | 1988-02-23 | Ointment and solution |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01213227A true JPH01213227A (en) | 1989-08-28 |
| JPH0546323B2 JPH0546323B2 (en) | 1993-07-13 |
Family
ID=12530366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3862388A Granted JPH01213227A (en) | 1988-02-23 | 1988-02-23 | Ointment and solution |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01213227A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022036987A (en) * | 2016-01-04 | 2022-03-08 | アヘンシア プブリカ エンプレサリアル サニタリア ホスピタル デ ポニエンテ | Composition for use in treatment of mucous membrane lesions using endoscopic resection |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4786630B2 (en) * | 2007-11-02 | 2011-10-05 | ロート製薬株式会社 | Topical skin preparation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61207310A (en) * | 1985-03-11 | 1986-09-13 | Shiseido Co Ltd | External agent for skin |
| JPS61236732A (en) * | 1985-04-05 | 1986-10-22 | フイデイ−ア・ソシエタ・ペル・アチオニ | Novel local medicine |
| JPS6245336A (en) * | 1985-08-21 | 1987-02-27 | Toyo Biyuut Kk | Emulsified composition |
| JPS62110722A (en) * | 1985-11-06 | 1987-05-21 | Nippon Denso Co Ltd | Air cleaner for internal combustion engine |
-
1988
- 1988-02-23 JP JP3862388A patent/JPH01213227A/en active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61207310A (en) * | 1985-03-11 | 1986-09-13 | Shiseido Co Ltd | External agent for skin |
| JPS61236732A (en) * | 1985-04-05 | 1986-10-22 | フイデイ−ア・ソシエタ・ペル・アチオニ | Novel local medicine |
| JPS6245336A (en) * | 1985-08-21 | 1987-02-27 | Toyo Biyuut Kk | Emulsified composition |
| JPS62110722A (en) * | 1985-11-06 | 1987-05-21 | Nippon Denso Co Ltd | Air cleaner for internal combustion engine |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022036987A (en) * | 2016-01-04 | 2022-03-08 | アヘンシア プブリカ エンプレサリアル サニタリア ホスピタル デ ポニエンテ | Composition for use in treatment of mucous membrane lesions using endoscopic resection |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0546323B2 (en) | 1993-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69733086T2 (en) | PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN KUUU NUTS OIL | |
| US4670185A (en) | Aqueous vesicle dispersion having surface charge | |
| US5002760A (en) | Retinol skin care composition | |
| US6096326A (en) | Skin care compositions and use | |
| JP4133837B2 (en) | Skin moisturizing gel and method | |
| CA2464436A1 (en) | Method and topical formulation for treating skin conditions associated with aging | |
| JP3487633B2 (en) | Skin disease treatment emulsion | |
| JPS59134706A (en) | Cosmetic | |
| JPH027287B2 (en) | ||
| US20080076831A1 (en) | Hemorrhoid reliever and method of use | |
| US20150216898A1 (en) | Composition for treating psoriasis | |
| US20110076261A1 (en) | Antifungal Drug Delivery System | |
| US20060088497A1 (en) | Topical skin care composition | |
| JPH09157172A (en) | Skin external agent and treating agent for eczema | |
| JP2000355515A (en) | Cosmetic composition | |
| IE922376A1 (en) | Topical anti-fungal agents having anti-inflammatory activity | |
| JPH09291012A (en) | Antiphlogistic skin cosmetic | |
| JPS60116618A (en) | Cosmetic | |
| JPH01213227A (en) | Ointment and solution | |
| JPH08291057A (en) | Cataplasm | |
| JP3479048B2 (en) | Cosmetics and non-woven fabric impregnated cosmetics | |
| JPH04360820A (en) | Cosmetic | |
| JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
| JPS6115813A (en) | Cosmetic for pack | |
| KR101733189B1 (en) | Composition for promotion of growing nail or toenail |